Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

871
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
871

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

iNOS is a key mediator of anti-PD-1 melanoma therapy response.

Frontiers in immunology·2026
Same author

Soft-tissue sarcoma with MN1-BEND2 fusion: second reported case and comparative analysis.

Journal of surgical case reports·2026
Same author

Invited Editorial about Article: "Salvage Metastasectomy after Adoptive Cell Transfer for Melanoma: Long-Term Updates" by Dinerman, Aaron et al.

Annals of surgical oncology·2026
Same author

Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapies.

Nature communications·2026
Same author

PETIL: Predicting Expansion of Tumor Infiltrating Lymphocytes for the Adoptive Cell Immunotherapy in Bladder Cancers.

bioRxiv : the preprint server for biology·2026
Same author

Transdermal bicarbonate buffer therapy increases intratumoral pH and elicits antitumor responses in bladder cancer.

Frontiers in immunology·2026

Related Experiment Video

Updated: Nov 21, 2025

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.5K

Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function.

John E Mullinax1,2, MacLean Hall2,3, Matthew Beatty2

  • 1Departments of Sarcoma.

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|January 14, 2021
PubMed
Summary

Tumor-infiltrating lymphocytes (TILs) can be successfully cultured and expanded from soft tissue sarcoma. These expanded TILs show tumor-specific reactivity, making them suitable for adoptive cell transfer (ACT) in clinical trials.

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.3K
Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
07:45

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Published on: January 26, 2024

2.4K

Related Experiment Videos

Last Updated: Nov 21, 2025

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.5K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.3K
Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
07:45

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Published on: January 26, 2024

2.4K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Adoptive cell transfer (ACT) using tumor-infiltrating lymphocytes (TILs) shows promise for treating advanced solid tumors.
  • Current challenges include efficient expansion of TILs from specific cancer types like soft tissue sarcoma.

Purpose of the Study:

  • To develop and validate methods for expanding tumor-reactive TILs from soft tissue sarcoma specimens.
  • To assess the feasibility and efficacy of TIL expansion for potential ACT applications.

Main Methods:

  • Fresh soft tissue sarcoma specimens were processed using fragment or digest methods for TIL culture.
  • TILs were analyzed for phenotype (flow cytometry) and tumor reactivity (interferon-γ ELISA).
  • A rapid expansion protocol was employed to achieve clinically relevant cell numbers.

Main Results:

  • High success rates for initial TIL culture were achieved (91% fragment, 100% digest).
  • Cultured TILs exhibited tumor-specific reactivity (56% fragment, 40% digest).
  • Significant expansion of TILs was demonstrated (median 490-fold fragment, 403-fold digest).

Conclusions:

  • Feasible methods for TIL culture and expansion from soft tissue sarcoma have been established.
  • Derived TILs possess tumor-specific reactivity and can be expanded to clinically relevant numbers.
  • These findings support an ongoing ACT clinical trial for metastatic soft tissue sarcoma.